Skip to main content
. 2021 Nov 16;75(2):221–229. doi: 10.1093/cid/ciab934

Table 2.

Secondary End Points of the Intention-to-Treat Population

Secondary End Point Fosfomycin (n=48) Ciprofloxacin (n=49) Risk Difference (95% Confidence Interval/P Value)
6–10 days post-end of therapy
  Microbiological cure 29/37 (78.4%) 33/35 (94.3%) –16.2% (–32.7% to –0.0%)
30–35 days post-end of therapy
  Clinical cure 35/47 (74.5%) 33/44 (75.0%) 0.4% (–18.4% to 17.6%)
  Reinfection 4/47 (8.5%) 7/44 (15.9%) –7.8% (–22.3% to 6.6%)
  Relapse 2/47 (4.3%) 0/44 5.2% (–4.0% to 14.3%)
  Additional antibiotic therapy for presumed urinary tract infection 6/47 (12.8%) 7/44 (15.9%) –3.4% (–18.6% to 11.9%)
  Length of hospital stay, mean (SD), days 4.4 (1.2) 5.4 (2.5) P=.9156a
  Hospital readmission (any cause) 3/48 (6.3%) 1/49 (2.0%) 5.0% (–5.3% to 15.2%)
  Absenteeism daysb mean (SD) 3.0 (6.7) 2.5 (7.0) P=.5508c
  Intensive care unit admissiona 1/48 (2.1%) 0/49 2.9% (–5.3% to 11.0%)
  Mortality (any cause) 2/48 (4.2%) 0/49 5.4% (–3.3% to 14.0%)
  Mortality (probably related) 0/48 0/49 NA

Abbreviation: SD, standard deviation.

After randomization.

Number of days absent from paid or voluntary work.

Calculated using a Mann-Whitney test.